Global Antifungal Market: Industry Analysis & Outlook (2016-2020) - Koncept Analytics

1
Industry Research by Koncept Analytics
Global Antifungal Market Industry Analysis
Outlook-----------------------------------------
(2016-2020)
November 2016
2
Executive Summary
Fungal infection is most common in those with
weakened immune system or those who have foreign
material, including medical devices in their body
like an artificial joint or heart valve. Fungal
infections are categorized under opportunistic
and primary fungal infection. Opportunistic
fungal infection targets weak immune patients and
can be very aggressive, spreading quickly to
other organs and often leading to death. While
primary fungal infection can occur in people with
a normal immune system, sometimes with serious
consequence. There are several types of
antifungal medicines. They come in as creams,
sprays, solutions, tablets designed to go into
the vagina (pessaries), shampoos, medicines to
take by mouth, and injections. Most work by
damaging the cell wall of the fungus, which
causes the fungal cell to die. The US is the
largest market of anti-fungal drugs. It has the
presence of the leading companies who specialize
in anti-fungal drugs. The key factors driving
growth of the anti-fungal market include rise in
incidences of fungal infections in
immuno-compromised patients, increase in number
of cancer patients, rise in incidences of fungal
infections in people suffering from AIDS,
increase in spending on medicines, rise in sale
of prescription drugs and many more. However,
market growth is hindered by the factors such as
harsh side effects of drugs, drug resistance,
high cost of anti-fungal, and lack of new
anti-fungal therapies. The major trends featuring
the market includes increase in development of
new drugs, flourishing public-private partnership
in pharmaceutical industry, and growing
awareness. The report offers an in-depth
analysis of the Global Anti-Fungal Market with
special focus on invasive anti-fungal segment. It
covers the regional and global aspects of the
market. The top notch players in the market
exhibit a very close competition. The report
profiles JNJ, Novartis, Pfizer, and Merck Co.
3
The global anti-fungal market is largely driven
by rise in population with weak immune system due
to cancer and other immunodeficiency syndrome.
Global Anti-Fungal Market by Value (2011-2015)

• The global anti-fungal market value reached US..
  billion in 2015, increasing from US.. billion in
  the previous fiscal year. The market grew at a
  CAGR of .. for the period spanning 2011-2015.
• The global invasive anti-fungal market is
  expected to reach US.. billion by 2020,
  increasing from US.. billion in 2016. The market
  is estimated to grow at a CAGR of .. for the
  period spanning 2016-2020.
• The global invasive anti-fungal markets majority
  of the share was held by XX drugs i.e. .. in
  2015.

Global Invasive Anti-Fungal Market by Drug Class
(2015)
Global Invasive Anti-Fungal Market Forecast by
Value (2016-2020)
4
With rise in incidences of fungal infections, the
need for better and cost effective drugs will
rise. This would create more opportunities.
Global Invasive Anti-Fungal Market by Target
Patients (2015)

• .. of the invasive fungal infections, are
  majorly caused by Candida fungi, happen to
  patients XX , followed by leukemia with ...
• The North American anti-fungal market value is
  expected to reach US.. billion by 2020,
  increasing from US.. billion in 2016, growing at
  a CAGR of .. from 2016-2020.
• European anti-fungal market value is estimated to
  reach US.. billion by 2020, increasing from
  US.. billion in 2016. The market is expected to
  grow at a CAGR of .. for the period spanning
  2016-2020.

Europe Anti-Fungal Market Forecast by Value
(2016-2020)
North America Anti-Fungal Market Forecast by
Value (2016-2020)
5
Disclaimer
Contact Us
This is a licensed product of Koncept Analytics.
You cannot reproduce, publish, distribute,
publicly display, sell or create other works from
this report or use them in any way for commercial
purpose without our prior permission. Further,
you cannot copy this material, by any means
(including electronic copies), for distribution
to others unless you have purchased the corporate
license of this report. We believe the sources
are reliable, but Koncept Analytics does not
warranty the accuracy or completeness of the
data. The data presented in the report is updated
at the publication date but is subject to change
at subsequent releases. All possible efforts have
been made to ensure accuracy of data. However,
investors should not completely rely on the
information given in this report and must make
decisions based on their own investment strategy,
risk management and capital adequacy.
Koncept Analytics CS-36, First Floor, Ansal
Plaza Vaishali, Ghaziabad, U.P. 201010 T
91-120-4130959 M 91-9811715635
vikas_at_konceptanalytics.com
www.konceptanalytics.com